MX2020009140A - Metodos para el tratamiento de enfermedades oculares. - Google Patents
Metodos para el tratamiento de enfermedades oculares.Info
- Publication number
- MX2020009140A MX2020009140A MX2020009140A MX2020009140A MX2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ocular diseases
- treating ocular
- treating
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643887P | 2018-03-16 | 2018-03-16 | |
| US201962805344P | 2019-02-14 | 2019-02-14 | |
| PCT/IB2019/051899 WO2019175727A1 (en) | 2018-03-16 | 2019-03-08 | Methods for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009140A true MX2020009140A (es) | 2020-09-28 |
Family
ID=66049363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009140A MX2020009140A (es) | 2018-03-16 | 2019-03-08 | Metodos para el tratamiento de enfermedades oculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210017266A1 (https=) |
| EP (1) | EP3765083A1 (https=) |
| JP (3) | JP6938796B2 (https=) |
| KR (2) | KR20200131839A (https=) |
| CN (1) | CN111867631A (https=) |
| AU (2) | AU2019235577B2 (https=) |
| CA (1) | CA3091096A1 (https=) |
| IL (2) | IL277333B2 (https=) |
| MX (1) | MX2020009140A (https=) |
| TW (1) | TWI727279B (https=) |
| WO (1) | WO2019175727A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| KR102050040B1 (ko) | 2008-06-25 | 2019-11-28 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| BRPI0914251B1 (pt) | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| KR20200131839A (ko) * | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| PE20211602A1 (es) | 2018-12-18 | 2021-08-18 | Novartis Ag | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| CN116195003A (zh) * | 2020-09-23 | 2023-05-30 | 基因泰克公司 | 对黄斑水肿患者的注射频率的机器学习预测 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| PE20260040A1 (es) | 2023-04-11 | 2026-01-09 | Ocular Therapeutix Inc | Implante ocular que contiene un inhibidor de la tirosina cinasa |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| BRPI0914251B1 (pt) | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| PE20181363A1 (es) * | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
| KR20200131839A (ko) * | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
-
2019
- 2019-03-08 KR KR1020207028377A patent/KR20200131839A/ko not_active Ceased
- 2019-03-08 AU AU2019235577A patent/AU2019235577B2/en active Active
- 2019-03-08 CA CA3091096A patent/CA3091096A1/en active Pending
- 2019-03-08 JP JP2020547357A patent/JP6938796B2/ja active Active
- 2019-03-08 MX MX2020009140A patent/MX2020009140A/es unknown
- 2019-03-08 IL IL277333A patent/IL277333B2/en unknown
- 2019-03-08 KR KR1020267006178A patent/KR20260036043A/ko active Pending
- 2019-03-08 EP EP19715998.1A patent/EP3765083A1/en active Pending
- 2019-03-08 CN CN201980017221.0A patent/CN111867631A/zh active Pending
- 2019-03-08 US US16/980,679 patent/US20210017266A1/en active Pending
- 2019-03-08 WO PCT/IB2019/051899 patent/WO2019175727A1/en not_active Ceased
- 2019-03-14 TW TW108108562A patent/TWI727279B/zh active
-
2021
- 2021-09-01 JP JP2021142541A patent/JP2021191778A/ja not_active Withdrawn
- 2021-12-14 AU AU2021286278A patent/AU2021286278C1/en active Active
-
2023
- 2023-12-15 JP JP2023212445A patent/JP2024042697A/ja not_active Withdrawn
-
2025
- 2025-10-09 IL IL323849A patent/IL323849A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3091096A1 (en) | 2019-09-19 |
| JP6938796B2 (ja) | 2021-09-22 |
| AU2021286278A1 (en) | 2022-01-20 |
| AU2021286278C1 (en) | 2024-05-23 |
| AU2021286278B2 (en) | 2023-09-14 |
| IL277333B1 (en) | 2025-11-01 |
| IL277333A (en) | 2020-10-29 |
| JP2021191778A (ja) | 2021-12-16 |
| RU2020133816A (ru) | 2022-04-18 |
| RU2020133816A3 (https=) | 2022-04-18 |
| JP2021509912A (ja) | 2021-04-08 |
| US20210017266A1 (en) | 2021-01-21 |
| EP3765083A1 (en) | 2021-01-20 |
| JP2024042697A (ja) | 2024-03-28 |
| CN111867631A (zh) | 2020-10-30 |
| TWI727279B (zh) | 2021-05-11 |
| KR20260036043A (ko) | 2026-03-13 |
| AU2019235577A1 (en) | 2020-08-27 |
| AU2019235577B2 (en) | 2021-09-30 |
| WO2019175727A1 (en) | 2019-09-19 |
| KR20200131839A (ko) | 2020-11-24 |
| IL277333B2 (en) | 2026-03-01 |
| TW201945027A (zh) | 2019-12-01 |
| IL323849A (en) | 2025-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009140A (es) | Metodos para el tratamiento de enfermedades oculares. | |
| CL2020003223A1 (es) | Anticuerpos il-11 | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| EA201692436A1 (ru) | Медицинское применение | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2015015228A (es) | Sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| MX2020007527A (es) | Tratamiento de enfermedades oftalmologicas. | |
| DOP2017000071A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| MX2021005038A (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas. | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| IL282827A (en) | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies | |
| SI3773558T1 (sl) | Kombinirano zdravljenje artritične bolezni | |
| MA45780B1 (fr) | Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| JOP20190056A1 (ar) | طرق لعلاج إصابة كلى حادة | |
| MX2022003101A (es) | Metodos de tratamiento de enfermedades oculares. | |
| MA53180A (fr) | Méthode de génération d'un descendance stérile | |
| IL281736A (en) | Methods of treating myeloproliferative disorders | |
| MX2022012906A (es) | Terapia con cer-001 para tratar enfermedad renal. |